How does CRSP compare to S&P 500?
Cirrus Logic (CRUS) operates as a fabless semiconductor designer specializing in high-performance low-power audio and mixed-signal IC solutions, positioning it uniquely against larger diversified chipmakers. Compared to broad-market analog competitors, Cirrus Logic maintains a high-concentration business model heavily tied to tier-one consumer electronics giants, most notably Apple, which accounts for a substantial share of its annual net sales. While this deep integration drives high revenue volume and design win efficiency during strong product cycles, it creates customer concentration risks that distinguish CRUS from competitors with more diversified client bases. Financially, CRUS stands out through robust research and development reinvestment, strong gross margins, and a specialized focus on audio processing innovation that preserves its competitive moat.
Related FAQs
Yes, Bill Gates's clean energy investment fund, Breakthrough Energy Ventures (BEV), announced an investment in Fervo Energy in 2018. Fervo Energy is a startup focused on pioneering "Enhanced Geothermal Systems" (EGS) technology.
Yes, Cathie Wood’s ARK Invest maintains a position in GitLab Inc. (GTLB) within its portfolio.
No, Charles River Laboratories International (CRL) does not pay a dividend to its shareholders.
Yes, CS Bank offers Zelle as a convenient and integrated digital payment service.
Companies operating within the CRISPR gene-editing and biotechnology sector are frequently viewed as potential strategic acquisition targets for massive global pharmaceutical conglomerates seeking innovative genetic medicine pipelines.
CRISPR gene-editing technologies are continuously advancing at an extraordinary pace, exhibiting enhanced precision, minimized off-target effects, and expanded clinical capabilities.
CRISPR Therapeutics, trading under the ticker CRSP, currently maintains a Buy consensus rating among Wall Street analysts as of July 2026.
As of July 2026, while CRISPR Therapeutics holds a Buy consensus rating among market professionals, it is not universally categorized as a Strong Buy.